HRP20251264T1 - Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom - Google Patents

Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom

Info

Publication number
HRP20251264T1
HRP20251264T1 HRP20251264TT HRP20251264T HRP20251264T1 HR P20251264 T1 HRP20251264 T1 HR P20251264T1 HR P20251264T T HRP20251264T T HR P20251264TT HR P20251264 T HRP20251264 T HR P20251264T HR P20251264 T1 HRP20251264 T1 HR P20251264T1
Authority
HR
Croatia
Prior art keywords
gemcitabine
bladder
per day
medicament
patient
Prior art date
Application number
HRP20251264TT
Other languages
English (en)
Croatian (hr)
Inventor
Dennis GIESING
Heejin Lee
Karen Daniel
Original Assignee
Taris Biomedical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical Llc filed Critical Taris Biomedical Llc
Publication of HRP20251264T1 publication Critical patent/HRP20251264T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HRP20251264TT 2014-03-06 2015-03-06 Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom HRP20251264T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461949215P 2014-03-06 2014-03-06
EP22196596.5A EP4124339B1 (en) 2014-03-06 2015-03-06 Drug delivery systems and methods for treatment of bladder cancer with gemcitabine

Publications (1)

Publication Number Publication Date
HRP20251264T1 true HRP20251264T1 (hr) 2025-12-05

Family

ID=52697553

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20251264TT HRP20251264T1 (hr) 2014-03-06 2015-03-06 Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
HRP20221252TT HRP20221252T1 (hr) 2014-03-06 2015-03-06 Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20221252TT HRP20221252T1 (hr) 2014-03-06 2015-03-06 Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s gemcitabinom

Country Status (24)

Country Link
US (3) US20150250717A1 (https=)
EP (2) EP4124339B1 (https=)
JP (5) JP6901858B2 (https=)
KR (1) KR102338079B1 (https=)
CN (2) CN106102751A (https=)
AU (4) AU2015226901B2 (https=)
BR (1) BR112016020381A8 (https=)
CA (1) CA2939979C (https=)
DK (2) DK4124339T3 (https=)
ES (2) ES2930435T3 (https=)
FI (1) FI4124339T3 (https=)
HR (2) HRP20251264T1 (https=)
HU (1) HUE060704T2 (https=)
IL (2) IL247347B2 (https=)
LT (2) LT4124339T (https=)
MX (1) MX2016011333A (https=)
PL (2) PL3113782T3 (https=)
PT (2) PT3113782T (https=)
RS (2) RS67337B1 (https=)
RU (1) RU2694902C1 (https=)
SG (2) SG11201607342QA (https=)
SI (1) SI4124339T1 (https=)
SM (2) SMT202200449T1 (https=)
WO (1) WO2015134911A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367070B (es) 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
KR102385603B1 (ko) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
LT4124339T (lt) * 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
CN118453872A (zh) * 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
BR112020000832A2 (pt) * 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) * 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法
EP4039279A4 (en) * 2019-10-03 2023-11-01 Seikagaku Corporation TRANSMUCOSAL MEDICINAL ACTIVE DELIVERY SYSTEM FOR THE BLADDER SUBMUCOSA
RU2713443C2 (ru) * 2019-11-01 2020-02-05 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения мышечно-инвазивного рака мочевого пузыря т3-т4 n0-+m0
US20230073301A1 (en) * 2020-01-27 2023-03-09 Isola Therapeutics, Inc. Tissue dosing for intraluminal local drug delivery
CN112169066B (zh) * 2020-10-29 2023-05-12 安徽省立医院(中国科学技术大学附属第一医院) 具有控制器的连续缓释给药留置管
CN113616666A (zh) * 2021-08-24 2021-11-09 傅广波 膀胱黏膜下注射吉西他滨在治疗膀胱癌中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US6171298B1 (en) 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
EP1372602B1 (en) 2001-01-09 2007-04-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
AU2003278881A1 (en) * 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
CA2503193A1 (en) 2002-10-22 2004-05-06 The Biomerix Corporation Method and system for intravesicular delivery of therapeutic agents
ATE387236T1 (de) * 2003-03-31 2008-03-15 Alza Corp Osmotische pumpe mit mitteln zum ableiten des innendrucks
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
DK1933810T3 (da) 2005-08-11 2013-01-28 Childrens Medical Center Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
KR101538748B1 (ko) 2007-12-11 2015-07-22 메사추세츠 인스티튜트 오브 테크놀로지 이식형 의약 투여 장치와 방광과 기타 신체 낭 또는 내강의 치료 방법
CA2720523C (en) 2008-04-04 2013-12-17 Lipella Pharmaceuticals, Inc. Treatment of bladder dysfunction using liposomal botulinum toxin
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US8721621B2 (en) 2009-09-10 2014-05-13 Taris Biomedical, Inc. Systems and methods for deploying devices to genitourinary sites
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
ES2732150T3 (es) * 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US20110218488A1 (en) 2010-03-05 2011-09-08 Taris Biomedical, Inc. Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites
WO2011153009A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
EP3795121A1 (en) 2010-08-05 2021-03-24 TARIS Biomedical LLC Ureteral stent drug delivery device
WO2012048114A1 (en) 2010-10-06 2012-04-12 Taris Biomedical, Inc. Time-selective bioresorbable or collapsible drug delivery systems and methods
US9457176B2 (en) 2010-10-06 2016-10-04 Taris Biomedical Llc Implantable drug delivery device with bladder retention feature
MX365807B (es) 2010-10-27 2019-06-14 Prometic Pharma Smt Ltd Compuestos y composiciones para el tratamiento del cáncer.
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
JP2014503554A (ja) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド 膀胱痛及び刺激性排尿の持続的治療の使用のためのリドカインレジメン
EP2670398B1 (en) * 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US20150005595A1 (en) 2011-12-30 2015-01-01 Kibur Medical, Inc. Implantable devices and methods for evaluation of active agents
CN104470535A (zh) 2012-03-29 2015-03-25 阿尔托生物科学有限公司 用于治疗肿瘤的方法
WO2013170069A1 (en) 2012-05-09 2013-11-14 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
MX367070B (es) * 2012-08-31 2019-08-05 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
SG11201501424SA (en) 2012-08-31 2015-03-30 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin
MX379066B (es) 2012-09-18 2025-03-04 Taris Biomedical Llc Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros trastornos del tracto urinario inferior.
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
EP2968120B1 (en) 2013-03-15 2026-01-14 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
KR102557326B1 (ko) * 2013-03-15 2023-07-19 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
KR102385603B1 (ko) * 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
EP3065807A1 (en) * 2013-11-05 2016-09-14 TARIS Biomedical LLC Osmotic drug delivery devices, kits, and methods
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
RU2591946C2 (ru) 2014-06-24 2016-07-20 Владимир Эдуардович Анников Способ изготовления гелеобразного водосодержащего взрывчатого состава
KR20220061253A (ko) 2014-06-26 2022-05-12 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
CN118453872A (zh) 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Also Published As

Publication number Publication date
AU2024259822A1 (en) 2024-11-28
PT3113782T (pt) 2023-01-05
CA2939979A1 (en) 2015-09-11
JP2022022235A (ja) 2022-02-03
IL247347B2 (en) 2025-03-01
AU2022215156A1 (en) 2022-09-01
IL311410A (en) 2024-05-01
ES2930435T3 (es) 2022-12-13
HUE060704T2 (hu) 2023-04-28
MX2016011333A (es) 2016-12-07
CN106102751A (zh) 2016-11-09
JP7802743B2 (ja) 2026-01-20
DK4124339T3 (da) 2025-10-13
BR112016020381A2 (pt) 2017-08-15
US20220347091A1 (en) 2022-11-03
EP3113782A1 (en) 2017-01-11
JP2017508749A (ja) 2017-03-30
US20150250717A1 (en) 2015-09-10
JP7061595B2 (ja) 2022-04-28
RS67337B1 (sr) 2025-11-28
SMT202500385T1 (it) 2025-11-10
IL311410B1 (en) 2025-07-01
CA2939979C (en) 2023-03-21
JP2024009034A (ja) 2024-01-19
ES3051417T3 (en) 2025-12-29
IL247347A0 (en) 2016-11-30
EP4124339A1 (en) 2023-02-01
EP4124339B1 (en) 2025-09-10
DK3113782T3 (da) 2022-10-17
LT3113782T (lt) 2022-11-25
SI4124339T1 (sl) 2025-11-28
JP7383681B2 (ja) 2023-11-20
AU2020217383A1 (en) 2020-09-03
KR20160124425A (ko) 2016-10-27
JP6901858B2 (ja) 2021-07-14
WO2015134911A1 (en) 2015-09-11
SG10202101978SA (en) 2021-04-29
BR112016020381A8 (pt) 2018-05-02
SMT202200449T1 (it) 2023-01-13
PL3113782T3 (pl) 2023-01-23
LT4124339T (lt) 2025-11-10
EP3113782B1 (en) 2022-09-28
AU2022215156B2 (en) 2024-09-05
RS63675B1 (sr) 2022-11-30
US12582599B2 (en) 2026-03-24
CN119950539A (zh) 2025-05-09
PL4124339T3 (pl) 2025-11-17
JP2026062972A (ja) 2026-04-10
US20220117886A1 (en) 2022-04-21
RU2694902C1 (ru) 2019-07-18
SG11201607342QA (en) 2016-10-28
NZ723303A (en) 2023-10-27
JP2019218410A (ja) 2019-12-26
IL311410B2 (en) 2025-11-01
AU2015226901B2 (en) 2020-05-14
AU2020217383B2 (en) 2022-09-08
FI4124339T3 (fi) 2025-10-17
PT4124339T (pt) 2025-11-04
IL247347B1 (en) 2024-11-01
KR102338079B1 (ko) 2021-12-09
AU2015226901A1 (en) 2016-09-01
HRP20221252T1 (hr) 2022-12-09

Similar Documents

Publication Publication Date Title
HRP20251264T1 (hr) Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
HRP20211921T1 (hr) Sustavi isporuke lijeka i postupci za liječenje raka mokraćnog mjehura s oksaliplatinom
JP2017508749A5 (https=)
MX2020002465A (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la disfuncion miccional de la vejiga y otros transtornos del tracto urinario inferior.
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
RU2016147523A (ru) Лечение гиперкинетических двигательных расстройств
WO2012071559A3 (en) Therapeutic methods and compositions for solid delivery
RU2015109298A (ru) Системы доставки лекарственного средства и способы лечения заболевания предстательной железы, включающие применение гемцитабина
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
HRP20191248T1 (hr) Kombinirana terapija za liječenje karcinoma jajnika
JP2018138596A5 (https=)
EP2424536A4 (en) NEW PHOTOSENSIBILIZER FORMULATIONS FOR ORAL ADMINISTRATION
HRP20181079T1 (hr) Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
HRP20250123T1 (hr) Spojevi za liječenje bolesti vezanih s lipofuscinom
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
AR111803A1 (es) Derivado de ciclopentan[g]quinazolin-4-ona y su empleo en el tratamiento de cáncer resistente al platino
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
CHEN et al. Clinical Observation of Oxaliplatin, Mitomycin and Doxorubicin Combined with Three-dimensional Con-formal Radiotherapy for Patients with Lack of Blood Supply Hepatocellular Carcinoma
Barsotti CMV lung infection, bladder infection and erythematous rash: 3 case reports
Robb-Nicholson By the way, doctor. I keep hearing that aspirin can help prevent colon cancer, but I have no idea how much I should take. Can you help? I've had adenomatous polyps in the past